RxDoctor Payments Data

Stephen Batter, MD

Urology · Norwalk, CTNPI 1619069754

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.9% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations.

$5,775in general payments, 2019–2025

Across 250 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$758
  • Astellas Pharma US Inc$748
  • 180 Medical, Inc.$421
  • Johnson & Johnson$347
  • Coloplast$291
  • Pfizer$253
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,30992%
  • Education$4668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,775 in reported general payments places this provider in the 70th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$298,383
Medicare patients
952
Services billed
4,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl2,095$45,123
MyrbetriqMirabegron41$44,511
GemtesaVibegron19$21,583
Finasteride824$12,682
Dutasteride273$12,282
Alfuzosin Hcl ErAlfuzosin Hcl202$4,683
Doxazosin Mesylate208$3,969
NitrofurantoinNitrofurantoin Macrocrystal50$991
Terazosin Hcl48$694
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst66$676
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$336
Oxybutynin Chloride ErOxybutynin Chloride15$325
Sildenafil Citrate17$200
Levofloxacin51$186
Ciprofloxacin Hcl26$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$748$44,51141 claims
Sumitomo Pharma America, Inc.Gemtesa$758$21,58319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 156 urology providers in Connecticut.

Other urology in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →